+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Congenital Hyperinsulinism Treatment Market by Indication Type, Treatment, Route of Administration, Distribution Channel, End-Users - Forecast 2024-2030

  • PDF Icon

    Report

  • 181 Pages
  • June 2024
  • Region: Global
  • 360iResearch™
  • ID: 5967489
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Congenital Hyperinsulinism Treatment Market grew from USD 182.53 million in 2023 to USD 192.20 million in 2024. It is expected to continue growing at a CAGR of 5.61%, reaching USD 267.64 million by 2030.

CHI treatment options are multifaceted, aiming to maintain blood glucose levels within a normal range and prevent hypoglycemic episodes. These include medical therapies such as diazoxide, octreotide, and newer drugs like lanreotide, as well as surgical interventions in more severe cases. The major factors contributing to the expansion of CHI treatment options include advancements in diagnostic methodologies, improved understanding of the genetic and molecular bases of the disease, and the development of novel pharmacological agents targeting specific pathways involved in insulin secretion. However, treatments for CHI come with challenges, including potential side effects, such as fluid retention with diazoxide or gastrointestinal symptoms with octreotide, and the risk of incomplete relief from symptoms or hypoglycemia recurrence. Addressing these challenges involves ongoing research into more targeted and less invasive therapeutic strategies, personalized medicine based on genetic profiling, and developing more effective and safer drugs. The advent of artificial pancreas systems that could regulate insulin production and release in real-time offers a transformative approach to managing CHI, providing advanced treatment for the condition.

Regional Insights

In the Americas, the congenital hyperinsulinism market is robust, with a high adoption rate of advanced treatments and active participation from leading pharmaceuticals, driven by a strong focus on research and development, particularly in the United States. Companies in the region have invested in various research & development (R&D) activities to support the introduction of advanced congenital hyperinsulinism treatment. The APAC scenario is marked by rapid growth fueled by increasing awareness and improving healthcare infrastructure, especially in countries such as China and India. EMEA presents a mixed environment with strong healthcare systems in Europe facilitating access to treatments and encouraging clinical trials, while the Middle East and Africa grapple with variability in healthcare access and quality. European companies have a significant presence in the market, indicative of the region's openness to innovative treatments and international collaborations. With government support for research activities, the region is witnessing an expansion of congenital hyperinsulinism treatment activities in hospitals & specialty clinics.

Market Insights

Market Dynamics

  • The market dynamics represent an ever-changing landscape of the Congenital Hyperinsulinism Treatment Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

  • Increase in prevalence of congenital hyperinsulinism disease
  • Government initiatives promoting congenital hyperinsulinism diagnosis

Market Restraints

  • Limited reimbursement available for congenital hyperinsulinism

Market Opportunities

  • Ongoing R&D for advancing treatment of congenital hyperinsulinism
  • Emerging approval of congenital hyperinsulinism treatments

Market Challenges

  • Diagnostic challenges and possible complications of the treatment

Market Segmentation Analysis

  • Indication Type: Need for a more personalized approach to treat Atypical CHI
  • End-Users: Need for a diverse range of treatments for congenital hyperinsulinism in hospitals

Industry Insights

  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Congenital Hyperinsulinism Treatment Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Congenital Hyperinsulinism Treatment Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

C-Path and Congenital Hyperinsulinism International Announce Data Sharing Agreement

The Critical Path Institute (C-Path) and Congenital Hyperinsulinism International (CHI) announced a data-sharing collaboration that sees the incorporation of invaluable patient-level data from CHI’s HI Global Registry into C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP), promising to significantly propel forward drug development efforts in the realm of rare diseases. HI, characterized by dangerously low blood sugar levels, poses severe health risks, including seizures, brain damage, and potential fatality.

Zealand Pharma Submits New Drug Application to US FDA for Dasiglucagon In Congenital Hyperinsulinism

Zealand Pharma A/S announced the submission of a New Drug Application (NDA) to the FDA for dasiglucagon, aiming to revolutionize the prevention and treatment of hypoglycemia in pediatric patients aged seven days and older suffering from congenital hyperinsulinism (CHI). By potentially offering dasiglucagon as a new treatment option, Zealand Pharma seeks to alleviate the extensive medical, psychosocial, and financial challenges faced by those living with CHI, marking a significant step forward in addressing this unmet medical need.

Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics

Rhythm Pharmaceuticals, Inc. announced the strategic acquisition of Xinvento B.V., a distinguished biotech enterprise based in the Netherlands that specializes in devising innovative treatments for congenital hyperinsulinism (CHI), a genetic disorder characterized by excessive insulin secretion leading to potentially life-threatening hypoglycemia. The acquisition is a pivotal extension of their pipeline into CHI therapy, aligning with the company’s strategic focus on rare endocrinology conditions, and expressed anticipation towards introducing a new therapeutic candidate into the clinical phase by 2024, addressing the critical need for innovative treatment options in the CHI domain.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Congenital Hyperinsulinism Treatment Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Congenital Hyperinsulinism Treatment Market, highlighting leading vendors and their innovative profiles. These include Crinetics Pharmaceuticals, Inc., Eiger Biopharmaceuticals Inc., Hanmi Pharmaceutical Company, Hua Medicine (Shanghai) Co., Ltd., Novartis AG, Rezolute, Inc., Rhythm Pharmaceuticals, Inc., Twist Bioscience Corporation, Xeris Biopharma Holdings, Inc., XOMA Corporation, and Zealand Pharma A/S.

Market Segmentation & Coverage

This research report categorizes the Congenital Hyperinsulinism Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

Indication Type

  • Atypical Congenital Hyperinsulinism
  • Diffuse Congenital Hyperinsulinism
  • Focal Congenital Hyperinsulinism

Treatment

  • Dietary Management

Drugs

  • Diazoxide
  • Glucagon
  • Nifedipine
  • Octreotide
  • Surgical Intervention

Route of Administration

  • Oral
  • Parenteral

Distribution Channel

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

End-Users

  • Ambulatory Surgery Centers
  • Hospitals
  • Specialty Clinics

Region

Americas

  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
  • California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas

Asia-Pacific

  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam

Europe, Middle East & Africa

  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increase in prevalence of congenital hyperinsulinism disease
5.1.1.2. Government initiatives promoting congenital hyperinsulinism diagnosis
5.1.2. Restraints
5.1.2.1. Limited reimbursement available for congenital hyperinsulinism
5.1.3. Opportunities
5.1.3.1. Ongoing R&D for advancing treatment of congenital hyperinsulinism
5.1.3.2. Emerging approval of congenital hyperinsulinism treatments
5.1.4. Challenges
5.1.4.1. Diagnostic challenges and possible complications of the treatment
5.2. Market Segmentation Analysis
5.2.1. Indication Type: Need for a more personalized approach to treat Atypical CHI
5.2.2. End-Users: Need for a diverse range of treatments for congenital hyperinsulinism in hospitals
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Congenital Hyperinsulinism Treatment Market, by Indication Type
6.1. Introduction
6.2. Atypical Congenital Hyperinsulinism
6.3. Diffuse Congenital Hyperinsulinism
6.4. Focal Congenital Hyperinsulinism
7. Congenital Hyperinsulinism Treatment Market, by Treatment
7.1. Introduction
7.2. Dietary Management
7.3. Drugs
7.4. Surgical Intervention
8. Congenital Hyperinsulinism Treatment Market, by Route of Administration
8.1. Introduction
8.2. Oral
8.3. Parenteral
9. Congenital Hyperinsulinism Treatment Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies
10. Congenital Hyperinsulinism Treatment Market, by End-Users
10.1. Introduction
10.2. Ambulatory Surgery Centers
10.3. Hospitals
10.4. Specialty Clinics
11. Americas Congenital Hyperinsulinism Treatment Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Congenital Hyperinsulinism Treatment Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Congenital Hyperinsulinism Treatment Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.3.1. C-Path and Congenital Hyperinsulinism International Announce Data Sharing Agreement
14.3.2. Zealand Pharma Submits New Drug Application to US FDA for Dasiglucagon In Congenital Hyperinsulinism
14.3.3. Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics
14.4. Strategy Analysis & Recommendation
15. Competitive Portfolio
15.1. Key Company Profiles
15.2. Key Product Portfolio
List of Figures
FIGURE 1. CONGENITAL HYPERINSULINISM TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CONGENITAL HYPERINSULINISM TREATMENT MARKET DYNAMICS
FIGURE 7. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2023 VS 2030 (%)
FIGURE 8. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
FIGURE 10. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 12. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 14. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
FIGURE 16. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 20. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 25. CONGENITAL HYPERINSULINISM TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 26. CONGENITAL HYPERINSULINISM TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. CONGENITAL HYPERINSULINISM TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ATYPICAL CONGENITAL HYPERINSULINISM, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ATYPICAL CONGENITAL HYPERINSULINISM, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DIFFUSE CONGENITAL HYPERINSULINISM, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DIFFUSE CONGENITAL HYPERINSULINISM, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY FOCAL CONGENITAL HYPERINSULINISM, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY FOCAL CONGENITAL HYPERINSULINISM, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DIAZOXIDE, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DIAZOXIDE, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY GLUCAGON, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY GLUCAGON, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY NIFEDIPINE, BY REGION, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY NIFEDIPINE, BY REGION, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY OCTREOTIDE, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY OCTREOTIDE, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 35. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
TABLE 36. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
TABLE 37. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2023 (USD MILLION)
TABLE 38. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2024-2030 (USD MILLION)
TABLE 39. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 40. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 41. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 42. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 43. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 44. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 45. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 46. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 47. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 48. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 49. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2023 (USD MILLION)
TABLE 50. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2024-2030 (USD MILLION)
TABLE 51. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
TABLE 52. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
TABLE 53. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 54. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 55. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 56. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 57. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 58. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 59. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 60. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 61. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 62. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 63. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 64. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 65. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 66. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 67. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 68. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 69. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 70. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 71. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 72. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 73. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 74. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 75. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 76. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 77. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 78. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 79. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 80. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 81. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 82. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 83. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 84. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 85. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 86. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 87. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 88. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 89. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 90. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 91. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 92. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 93. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 94. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 95. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 96. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 97. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 98. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 99. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 100. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 101. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 102. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 103. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 104. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 105. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 106. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 107. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 108. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 109. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 110. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 111. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 112. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 113. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 114. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 115. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 116. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 117. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 118. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 119. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 120. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 121. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 122. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 123. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 124. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 125. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 126. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 127. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 128. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 129. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 130. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 131. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 132. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 133. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 134. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 135. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 136. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 137. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 138. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 139. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 140. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 141. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 142. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 143. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 144. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 145. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 146. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 147. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 148. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 149. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 150. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 151. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 152. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 153. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 154. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 155. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 156. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 157. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 158. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 159. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 160. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 161. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 162. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 163. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 164. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 165. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 166. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 167. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 168. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 169. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 170. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 171. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 172. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 173. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 174. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 175. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 176. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 177. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 178. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 179. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 180. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 181. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 182. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 183. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 184. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 185. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 186. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 187. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 188. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 189. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 190. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 191. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 192. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 193. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 194. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 195. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 196. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 197. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 198. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 199. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 200. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 201. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 202. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 203. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 204. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 205. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 206. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 207. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 208. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 209. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 210. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 211. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 212. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 213. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 214. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 215. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 216. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 217. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 218. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 219. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 220. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 221. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 222. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 223. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 224. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 225. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 226. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 227. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 228. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 229. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 230. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 231. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 232. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 233. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 234. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 235. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 236. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 237. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 238. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 239. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 240. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 241. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 242. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 243. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 244. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 245. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 246. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 247. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 248. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 249. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 250. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 251. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 252. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 253. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 254. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 255. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 256. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 257. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 258. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 259. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 260. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 261. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 262. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 263. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 264. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 265. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 266. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 267. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 268. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 269. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 270. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 271. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 272. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 273. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 274. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 275. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 276. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 277. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 278. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
TABLE 279. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 280. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 281. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 282. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 283. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 284. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 285. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 286. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 287. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 288. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 289. EUROPE, MIDDLE EAST & AFRICA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
TABLE 290. EUROPE, MIDDLE EAST & AFRICA CONGENITAL HYPERINSULINISM TREATMENT MARKET S

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Crinetics Pharmaceuticals, Inc.
  • Eiger Biopharmaceuticals Inc.
  • Hanmi Pharmaceutical Company
  • Hua Medicine (Shanghai) Co., Ltd.
  • Novartis AG
  • Rezolute, Inc.
  • Rhythm Pharmaceuticals, Inc.
  • Twist Bioscience Corporation
  • Xeris Biopharma Holdings, Inc.
  • XOMA Corporation
  • Zealand Pharma A/S

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages181
PublishedJune 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 192.2 Million
Forecasted Market Value ( USD ) by 2030 $ 267.64 Million
Compound Annual Growth Rate5.6%
Regions CoveredGlobal

Related Topics

Related Reports

Congenital Hyperinsulinism Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Congenital Hyperinsulinism Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 134 Pages
  • Global
From
Congenital Hyperinsulinism - Pipeline Insight, 2024 - Product Image

Congenital Hyperinsulinism - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From
Insulin. Deficiency, Excess and Resistance in Human Disease - Product Image

Insulin. Deficiency, Excess and Resistance in Human Disease

  • Book
2024 Global Forecast for the Congenital Hyperinsulinism Market (2025-2030 Outlook) - High Tech & Emerging Markets Report - Product Image

2024 Global Forecast for the Congenital Hyperinsulinism Market (2025-2030 Outlook) - High Tech & Emerging Markets Report

  • Report
  • 132 Pages
  • Global
From
Polycystic ovary syndrome - Pipeline Insight, 2024 - Product Image

Polycystic ovary syndrome - Pipeline Insight, 2024

  • Drug Pipelines
  • 60 Pages
  • Global
From

About the Congenital Hyperinsulinism Drug Market

Congenital Hyperinsulinism (CHI) is a rare endocrine disorder caused by an overproduction of insulin. It is characterized by persistent hypoglycemia, which can lead to seizures, coma, and even death if left untreated. Treatment for CHI typically involves the use of drugs to reduce the amount of insulin produced by the body. These drugs are known as Congenital Hyperinsulinism Drugs (CHID). CHID are typically used in combination with dietary and lifestyle modifications to reduce the risk of hypoglycemia. Commonly used CHID include diazoxide, octreotide, and somatostatin analogs. These drugs work by blocking the release of insulin from the pancreas, thereby reducing the amount of insulin in the body. CHID are an important part of the endocrine and metabolic disorder drug market. They are used to treat a wide range of endocrine and metabolic disorders, including CHI, diabetes, and obesity. Companies in the CHID market include Novo Nordisk, Sanofi, Eli Lilly, and Merck. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.